James Sapirstein

Insider Reports History

Identity Names, identifiers, and filing context for this profile. 1 identity field
Reporting-owner location
Houston, TX
SEC source record Original filing metadata and source links for verification. 1 source field
Latest reporting-owner signature
/s/ James Sapirstein
Source: Latest parsed Forms 3/4/5 signature
Source evidence Original filing metadata and source links for verification. 1 source field
Transaction source note
Rows are grouped by transaction date from the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.

Reported holdings for James Sapirstein

Form 4 holding Chairman and CEO, Director

Entero Therapeutics, Inc.

Security class
Common Stock
Shares / value
35,816
Estimated value
$38,323
Report date
02 Jul 2024
Price
$1.07
Ownership
Direct
Form 4 holding Director

Onconetix, Inc.

Security class
Common Stock
Shares / value
3,477
Estimated value
$26,098
Report date
26 Sep 2024
Price
$4.10
Ownership
Direct
Form 4 holding Chief Executive Officer

Cocrystal Pharma, Inc.

Security class
Stock Options (Right to Buy)
Shares / value
235,000
Estimated value
Report date
03 Jun 2026
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Director

RENOVARO INC.

Security class
Option to purchase shares of common stock
Shares / value
48,137
Estimated value
Report date
25 Jun 2024
Price
Ownership
Direct
Underlying class
Common stock
Underlying amount
Form 4 holding Director

RENOVARO INC.

Security class
Option to Purchase Common Stock
Shares / value
28,196
Estimated value
Report date
06 Mar 2024
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Director

ZyVersa Therapeutics, Inc.

Security class
Stock Options
Shares / value
132
Estimated value
Report date
24 May 2023
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount

Insider Reports Filed by James Sapirstein

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .